Chardan Capital Initiates Coverage On Purple Biotech with Buy Rating, Announces Price Target of $11
Chardan Capital analyst Matthew Barcus initiates coverage on Purple Biotech (NASDAQ:PPBT) with a Buy rating and announces Price Target of $11.